Genesis Biotechnology Group® (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD3) announced today that it has acquired the Cincinnati-based CRO STATKING Clinical Services.
|
HAMILTON, N.J., Jan. 6, 2021 /PRNewswire/ -- Genesis Biotechnology Group® (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD3) announced today that it has acquired the Cincinnati-based CRO STATKING Clinical Services. Established in 1989, STATKING provides clinical trial services, including clinical trial management, protocol development, biostatistics, clinical data management, clinical study monitoring, medical writing, medical monitoring, safety reporting, and project management for the regulatory approval of novel drug and medical device products. "We are very pleased to have STATKING join GBG, and this acquisition demonstrates our commitment to making GD3 a fully integrated concept to commercialization CRO," said Eli Mordechai, Ph.D., Chief Executive Officer (CEO) of GBG. "STATKING's acquisition strengthens our services and strategic presence throughout the life cycle of the drug development process. STATKING has achieved significant milestones in its 30 years of service, and I look forward to an exciting future together." "The way pharma companies work with CROs is changing. CROs are taking more of a strategic planning role, in addition to execution, in the drug discovery and development process. This model of engagement results in sponsors and CROs becoming end-to-end partners, and M&A is helping CRO's extend their service portfolio to partner with their customers in providing greater efficiency in service and delivery across R&D continuum. The acquisition of STATKING would bring GD3 one more step closer to becoming a full service CRO," said Ben Bandaru, Ph.D., Director of Corporate Development for GBG. "STATKING and GD3 share a common vision that delivering better therapies to patients faster requires an integration of drug discovery and clinical trial services," said Rod Lashley. The addition of STATKING's clinical services to GD3's integrated, early-late stage drug discovery solutions will create a unique platform for clients to work with one scientific partner to enhance the speed and efficiency with which they can advance their therapies into the clinics. About GBG About Genesis Drug Discovery & Development About STATKING Clinical Services To find out more, please visit https://gd3services.com/. Contact:
SOURCE Genesis Biotechnology Group |
View original content to download multimedia:
